Altus Biologics

04/01/2026

Researchers found that people within five years of an MS diagnosis who followed the MIND diet had healthier brain tissue in regions important for communication.

03/30/2026

Today on National Doctors’ Day, Altus Biologics recognizes the skill, discipline, and steady commitment of our partner physicians. 🩺

Every day, providers make complex clinical decisions, advocate for their patients, and carry the responsibility of care with both precision and compassion.

To our partner physicians, thank you for the work you do and for letting us support the continuum of care alongside you. 🤝

03/27/2026

Ileocolitis is the most common type of Crohn’s disease, affecting the end of the small intestine and the colon.

03/26/2026

Spring 🌻 can feel like a fresh start, but for many people living with autoimmune conditions, it can also bring unexpected symptom changes.

If you have rheumatoid arthritis, lupus, asthma, or another chronic inflammatory condition, you may notice that your body does not always adjust smoothly to 🗓️ seasonal change.

Changing Seasons, Changing Symptoms: Why Spring Can Affect Autoimmune Conditions. Altus Biologics Partnering with Physicians to Provide Biologic Management Services

03/25/2026

FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis.

Sun Pharmaceutical's Ilumya receives FDA nod for label expansion to treat active psoriatic arthritis, following positive Phase 3 clinical trial results. Discover how this innovative therapy aims to become a leading choice for patients.

03/24/2026

Research shows oral health can affect the whole body and may even raise the risk of lupus flares, so people with lupus should see a dentist every six months.

03/22/2026

For respiratory 🫁 specialty practices, prescribing biologic therapies often comes with a complex layer of coverage verification, prior authorization requirements, payer-specific criteria, and ongoing coordination responsibilities.

These barriers can slow treatment initiation, increase staff workload, and create friction in the patient journey.

Improving Access to Biologics for Severe Asthma Management. Altus Biologics Partnering with Physicians to Provide Biologic Management Services

03/19/2026

Everyone’s experience with rheumatoid arthritis is different, but what all patients share is the 🔀 unpredictability associated with this chronic disease.

Staying consistent ✔ with your treatment plan is one of the most important steps you can take to protect your long-term health and mobility.

Living With Rheumatoid Arthritis: Why Staying on Your Treatment Matters. Altus Biologics Partnering with Physicians to Provide Biologic Management Services

03/18/2026

Regular cognitive training and mentally stimulating activities can help slow or reduce the cognitive effects of MS. Keep learning new skills and stay engaged in challenging work and leisure pursuits.

03/17/2026

🌸 Altus Biologics is excited to attend the 2026 Cherry Blossom Allergy Conference (CBAC)taking place March 27–29 in Washington, DC.

📍If you’re attending the conference, be sure to stop by the Altus Biologics booth and connect with our Sales Director, Greg Tutko. Greg will be there to discuss how our biologic therapy management solutions help allergy and asthma practices streamline biologic programs, improve patient access, and reduce administrative burden for clinical teams.

Whether you’re currently offering biologics or considering expanding your program, we’d love to talk about how Altus Biologics can support your practice and your patients.

We hope to see you in Washington, DC! 👋

03/16/2026

Recently, we kicked off our first annual Remedy Specialty Network National Sales Meeting in Nashville, TN! 🎉

We discussed our strategy and growth plans 📈 for our Infusion, GPO, Specialty Distribution, and Specialty Pharmacy businesses for 2026 and beyond.

Excited for our future together as 🌐 one network!

03/16/2026

Asthma Biologics Not Tied to Increased Respiratory Infections.

Biologics including Dupilumab and anti-IL-5 agents were associated with a lower probability of pneumonia within the study.